BioSpace News Archive

Aptose Biosciences Inc. will report financial results for the fourth quarter and full year ended December 31, 2022, on Thursday, March 23, 2023, after the close of the market, and provide a corporate update.

Clearside Biomedical, Inc. reported financial results for the fourth quarter and year ended December 31, 2022 and provided a corporate update.

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the fourth quarter and full year 2022.

Codexis, Inc., a leading enzyme engineering company, announced the approval of equity grants to two new employees as approved by the Compensation Committee of Codexis’s Board of Directors.

Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the fourth quarter and full year ended December 31, 2022, and highlighted recent accomplishments.

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report fourth quarter and full year 2022 financial results on Wednesday, March 22, 2023, after the close of the market.

Trevi Therapeutics, Inc. today announced that senior management will host a conference call and live audio webcast on Thursday, March 16, 2023, at 4:30 p.m. ET, to provide a corporate update and review the Company’s financial results for the fourth quarter and full year ended December 31, 2022.

Sporos BioDiscovery, Inc. today announced the company’s Executive in Residence, Stephen Rubino, Ph.D., will present a company overview on Wednesday, March 15, 2023, at 12:40 p.m. ET at the Oppenheimer 33rd Annual Healthcare Conference, which will take place virtually.

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced updates and financial results for the fourth quarter and full year ended December 31, 2022.

Eagle Pharmaceuticals, Inc. will participate in a fireside chat at the Barclays Global Healthcare Conference, in Miami, FL.